US FDA approves Pfizer’s inflammatory bowel illness drug
A corporate brand is observed at a Pfizer place of job in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/Record Picture Achieve Licensing RightsOct 13 (Reuters) – The U.S. Meals and Drug Management
